Literature DB >> 16728573

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

L Fugazzola1, E Puxeddu, N Avenia, C Romei, V Cirello, A Cavaliere, P Faviana, D Mannavola, S Moretti, S Rossi, M Sculli, V Bottici, P Beck-Peccoz, F Pacini, A Pinchera, F Santeusanio, R Elisei.   

Abstract

Recently, a somatic point mutation of the B-RAF gene (V600E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a prevalence variable among different series. Since discordant data on the clinico-pathologic features of B-RAF mutated PTC are present in the literature, the aim of the present co-operative study was to establish the prevalence of this genetic alteration and to perform a genotype-phenotype correlation in a large cohort of patients with PTC. To this purpose, a series of 260 sporadic PTCs with different histological variants were included in the study. The mutational analysis of the B-RAF gene was performed either by RT-PCR followed by single-stranded conformational polymorphism or by PCR and direct sequencing. Statistical analyses were obtained by means of chi2/Fisher's exact test and t-test. Overall, a heterozygous T > A transversion at nucleotide 1799 (V600E) was found in 99 out of 260 PTCs (38%). According to the histological type of the tumor, the B-RAF (V600E) mutation was present in 48.3% of cases of classic PTCs (85 out of 176), in 17.6% (nine out of 51) of follicular variants of PTCs, in 21.7% (five out of 23) in other PTC variants and in none of the ten poorly differentiated tumors. B-RAF (V600E) was significantly associated with the classic variant of PTC (P = 0.0001) and with an older age at diagnosis (P = 0.01). No statistically significant correlation was found among the presence of B-RAF (V600E) and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome. In conclusion, the present study reports the prevalence of B-RAF (V600E) (38%) in the largest series of sporadic PTCs, including 260 cases from three different Italian referring centers. This prevalence is similar to that calculated by pooling together all data previously reported, 39.6% (759 out of 1914 cases), thus indicating that the prevalence of this genetic event lies around 38-40%. Furthermore, B-RAF (V600E) was confirmed to be associated with the papillary growth pattern, but not with poorer differentiated PTC variants. A significant association of B-RAF mutation was also found with an older age at diagnosis, the mutation being very rare in childhood and adolescent PTCs. Finally, no correlation was found with a poorer prognosis and a worse outcome after a median follow-up of 72 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728573     DOI: 10.1677/erc.1.01086

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  63 in total

1.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

2.  Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.

Authors:  Jonathan R George; Ying C Henderson; Michelle D Williams; Dianna B Roberts; Hu Hei; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2015-10-13       Impact factor: 5.958

3.  Differentiated thyroid tumors: surgical indications.

Authors:  R Lucchini; M Monacelli; S Santoprete; R Triola; C Conti; R Pecoriello; P Favoriti; M S Di Patrizi; I Barillaro; A Boccolini; S Avenia; M D'Ajello; A Sanguinetti; N Avenia
Journal:  G Chir       Date:  2013 May-Jun

4.  Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.

Authors:  S H Kim; J G Kang; C S Kim; S H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

5.  In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.

Authors:  Almira Nasirden; Tsuyoshi Saito; Yuki Fukumura; Kieko Hara; Keisuke Akaike; Aiko Kurisaki-Arakawa; Miki Asahina; Atsushi Yamashita; Ran Tomomasa; Takuo Hayashi; Atsushi Arakawa; Takashi Yao
Journal:  Virchows Arch       Date:  2016-10-07       Impact factor: 4.064

6.  BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI).

Authors:  Hong Xie; Bojun Wei; Hong Shen; Ying Gao; Lingling Wang; Hui Liu
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

7.  BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Authors:  Neslihan Kurtulmus; Mete Duren; Umit Ince; M Cengiz Yakicier; Onder Peker; Ozlem Aydın; Ender Altiok; Serdar Giray; Halil Azizlerli
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

8.  A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Authors:  Claudia Martinuzzi; Lorenza Pastorino; Virginia Andreotti; Anna Garuti; Michele Minuto; Roberto Fiocca; Giovanna Bianchi-Scarrà; Paola Ghiorzo; Federica Grillo; Luca Mastracci
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

9.  The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Authors:  Electron Kebebew; Julie Weng; Juergen Bauer; Gustavo Ranvier; Orlo H Clark; Quan-Yang Duh; Daniel Shibru; Boris Bastian; Ann Griffin
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

10.  Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.

Authors:  Bálint Tobiás; Csaba Halászlaki; Bernadett Balla; János P Kósa; Kristóf Árvai; Péter Horváth; István Takács; Zsolt Nagy; Evelin Horváth; János Horányi; Balázs Járay; Eszter Székely; Tamás Székely; Gabriella Győri; Zsuzsanna Putz; Magdolna Dank; Zsuzsanna Valkusz; Béla Vasas; Béla Iványi; Péter Lakatos
Journal:  Pathol Oncol Res       Date:  2015-08-11       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.